Isomorphic Labs raised $2.1 billion in a Series B round with MGX among its new investors. The Alphabet-backed AI drug discovery company is using the capital to scale its drug design engine and push its first compounds toward clinical trials.
Abu Dhabi's technology investment vehicle MGX has joined one of the most significant funding rounds in the history of AI-driven drug discovery. Isomorphic Labs raised $2.1 billion in Series B funding on May 12, 2026, led by Thrive Capital with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. The round brings Isomorphic's total capital raised to approximately $2.6 billion and pushes it firmly into the tier of the most heavily backed private AI companies in the world, not in software or infrastructure, but in pharmaceutical science.
Isomorphic Labs was founded in 2021 as a spinout from Google DeepMind, built to commercialise AlphaFold, the protein structure prediction model that earned its creators a Nobel Prize. The company is led by Sir Demis Hassabis, who simultaneously serves as CEO of Google AI, a dual role that has given Isomorphic a unique position at the intersection of the world's most powerful AI research infrastructure and the life sciences industry's appetite for faster, cheaper drug development. The ambition Hassabis has articulated consistently, using AI to solve all disease, is not a marketing phrase. It is the framing that has attracted serious capital from serious investors across three continents.
The new capital will go toward the continued development and deployment of Isomorphic's AI Drug Design Engine, known as IsoDDE, and toward accelerating and expanding its pipeline of therapeutic programs toward the clinic. The funding will also support hiring across AI, engineering, drug design, and clinical disciplines globally. IsoDDE is not a single model but a unified platform of proprietary AI systems capable of working across multiple therapeutic areas and drug modalities, from cancer to immune disorders. The platform builds on AlphaFold's protein structure prediction capabilities and extends them into active drug design, predicting how candidate molecules will interact with biological targets and how to optimize those interactions before any compound is synthesized in a lab.
The partnership portfolio sitting alongside the internal pipeline gives Isomorphic a dual engine for both revenue and validation. The company holds multi-billion-dollar research and development partnerships with Novartis, Eli Lilly, and Johnson & Johnson, relationships that serve as both a proving ground for IsoDDE and a source of large-scale biological data that feeds back into the platform's training and development. No human patient has been dosed with an Isomorphic-designed compound yet, but the company has begun pre-clinical work and is targeting clinical trial entry before the end of 2026, a timeline Hassabis described as representing a genuine transition from model development to medical application.
Hassabis described the round as a massive vote of confidence from a diverse group of top-tier international investors, and said the focus now is on scaling the technology to its full potential after demonstrating the fundamental soundness of the approach.
For MGX, the participation in Isomorphic's Series B is consistent with the Abu Dhabi fund's strategy of backing frontier technology companies at the intersection of AI and critical global sectors. MGX has previously participated in OpenAI's investment round and has been actively deploying capital across AI infrastructure and application companies globally. Adding an AI drug discovery platform at the scale and credibility of Isomorphic to that portfolio reflects a view that the next wave of AI value creation will be in scientific domains, not just in software and infrastructure. For the broader MENA region, the investment is a signal that Gulf sovereign capital is now a meaningful participant in the deepest layers of the global AI economy, including areas like drug discovery where the research timelines are long, the stakes are high, and the returns, if the science works, could be transformative.
